AIVITA Biomedical Announces 96% Immune Response Against SARS-CoV-2 in Phase 2 Clinical Trial of a Personalized Vaccine

IRVINE, Calif.: IRVINE, Calif., Sept. 13, 2021 /PRNewswire/ -- AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative cell therapies, today announced results from its Phase 2 clinical study testing AIVITA's anti-SARS-CoV-2 Vaccine Enabling Kit, which allows any minimally-equipped facility to make personalized COVID-19 vaccines during the course of...

Click to view original post